<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Hepatitis C</title>
	<atom:link href="http://www.tapanray.in/tag/hepatitis-c/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>An Aggressive New Drug Pricing Trend: What It Means To India?</title>
		<link>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-aggressive-new-drug-pricing-trend-what-it-means-to-india</link>
		<comments>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/#comments</comments>
		<pubDate>Mon, 27 Oct 2014 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[aggressive]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmony]]></category>
		<category><![CDATA[HCV. Sovaldi]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Script]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6134</guid>
		<description><![CDATA[A new class and an aggressive drug-pricing trend is now evolving in the global pharmaceutical industry, exerting huge financial pressure on the patients and payers, including governments, especially, in the developed nations of the world. Another aspect of this issue &#8230; <a href="http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-aggressive-new-drug-pricing-trend-what-it-means-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
